logo
Plus   Neg
Share
Email

Stock Alert: Supernus Pharmaceuticals Up 14% On Positive Trial Results Of ADHD Drug

Shares of Supernus Pharmaceuticals, Inc. (SUPN) are currently gaining nearly 14%. The company on Tuesday after the bell revealed positive results from a study of its potential drug for attention deficit hyperactivity disorder, or ADHD.

SUPN is currently trading at $25.67, up $3.15 or 13.99%, on the Nasdaq.

Supernus announced that the phase 3 study of SPN-812 met the primary endpoint with robust statistical significance.

SPN-812 is under review by the U.S. Food and Drug Administration for the treatment of ADHD in pediatric patients 6 to 17 years of age. Supernus plans to ask for the drug to be considered for adults as well if it is approved by the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
South Korea's Hyundai Motor Co. announced its decision to suspend production at its Asan plant for two days starting on Monday due to a chip shortage amid the pandemic crisis, Reuters reported. The company is experiencing trouble in supply conditions for semiconductor parts for powertrain control units. The Asan factory manufactures 300,000 vehicles, including the Sonata and Grandeur sedans, each The U.S. Department of Health and Human Services is set to expand its Health Center COVID-19 Vaccine Program to include all HRSA-funded health centers. This will increase the total number of health centers that have been invited to join the program to 1,470 nationwide from the earlier 950. McDonald's Corp. is planning to hire 25,000 workers in its restaurants across Texas in April, reports said. In a three-day event from April 13 to 15, the fast-food chain is expected to hire for crew and management positions. During these hiring days, participating McDonald's restaurants in the state will be accepting applications and interviewing job seekers.
RELATED NEWS
Follow RTT